TABLE 1.
In vitro susceptibilities to 10 antimicrobial agents for clinical isolates of P. aeruginosa collected from 1999 to 2002a
| Antimicrobial agent(s) | Yr | % Susceptible
|
% Intermediate
|
% Resistant
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-ICU | ICU | NH | OP | Combined | Non-ICU | ICU | NH | OP | Combined | Non-ICU | ICU | NH | OP | Combined | ||
| Amikacin | 1999 | 86.0 | 91.3 | 93.4 | 88.6 | 87.7 | 3.9 | 4.8 | 5.3 | 4.3 | 4.1 | 10.1 | 3.9 | 1.3 | 7.1 | 8.2 |
| 2000 | 88.9 | 87.9 | 92.3 | 83.8 | 86.8 | 4.6 | 7.0 | 3.1 | 6.6 | 5.7 | 6.4 | 5.1 | 4.6 | 9.6 | 7.5 | |
| 2001 | 91.8 | 89.5 | 95.2 | 82.1 | 88.7 | 3.8 | 3.4 | 3.1 | 5.8 | 4.3 | 4.4 | 7.2 | 1.7 | 12.1 | 6.9 | |
| 2002 | 92.1 | 89.6 | 93.0 | 88.5 | 90.8 | 3.4 | 4.5 | 4.8 | 4.5 | 4.0 | 4.5 | 5.9 | 2.2 | 7.0 | 5.2 | |
| 1999-2002 | 90.6 | 89.4 | 94.0 | 85.4 | 89.0 | 3.8 | 4.8 | 4.0 | 5.4 | 4.4 | 5.5 | 5.7 | 2.0 | 9.2 | 6.6 | |
| Cefepime | 1999 | 75.6 | 79.5 | 81.6 | 82.7 | 78.4 | 13.3 | 13.5 | 17.1 | 11.7 | 12.9 | 11.1 | 7.0 | 1.3 | 5.6 | 8.8 |
| 2000 | 75.3 | 66.9 | 76.9 | 78.5 | 75.3 | 13.1 | 17.3 | 15.4 | 12.4 | 13.5 | 11.6 | 15.7 | 7.7 | 9.1 | 11.2 | |
| 2001 | 77.3 | 73.4 | 73.1 | 78.8 | 77.0 | 13.5 | 14.9 | 19.3 | 12.6 | 13.8 | 9.2 | 11.7 | 7.6 | 8.6 | 9.2 | |
| 2002 | 75.7 | 64.2 | 72.9 | 83.4 | 76.4 | 14.9 | 19.0 | 18.4 | 10.6 | 14.3 | 9.4 | 16.8 | 8.7 | 6.0 | 9.2 | |
| 1999-2002 | 76.1 | 69.6 | 73.3 | 80.7 | 76.6 | 13.9 | 16.7 | 18.7 | 11.8 | 13.8 | 10.0 | 13.7 | 7.9 | 7.5 | 9.5 | |
| Ceftazidime | 1999 | 77.9 | 83.2 | 92.1 | 86.9 | 81.5 | 5.2 | 4.5 | 3.9 | 4.7 | 4.9 | 17.0 | 12.4 | 3.9 | 8.4 | 13.6 |
| 2000 | 76.9 | 72.9 | 84.6 | 86.1 | 79.9 | 7.7 | 8.1 | 3.1 | 4.7 | 6.6 | 15.4 | 19.0 | 12.3 | 9.2 | 13.5 | |
| 2001 | 75.2 | 72.2 | 57.0 | 83.5 | 76.2 | 11.1 | 9.6 | 26.3 | 6.3 | 10.6 | 13.6 | 18.2 | 16.7 | 10.2 | 13.2 | |
| 2002 | 75.0 | 65.0 | 64.0 | 85.8 | 76.3 | 11.9 | 13.5 | 22.6 | 7.2 | 11.4 | 13.1 | 21.6 | 13.4 | 6.9 | 12.3 | |
| 1999-2002 | 75.8 | 71.5 | 62.1 | 85.3 | 77.6 | 10.0 | 9.8 | 23.3 | 6.1 | 9.4 | 14.2 | 18.7 | 14.6 | 8.7 | 13.0 | |
| Ciprofloxacin | 1999 | 61.6 | 74.4 | 60.5 | 62.3 | 63.8 | 10.5 | 6.9 | 6.6 | 10.1 | 9.8 | 27.9 | 18.8 | 32.9 | 27.6 | 26.5 |
| 2000 | 62.4 | 66.6 | 69.2 | 66.6 | 64.7 | 6.7 | 4.5 | 1.5 | 7.7 | 6.7 | 30.9 | 28.9 | 29.2 | 25.7 | 28.6 | |
| 2001 | 60.5 | 67.5 | 43.0 | 64.4 | 61.1 | 5.8 | 5.1 | 8.6 | 8.4 | 6.8 | 33.6 | 27.3 | 48.4 | 27.3 | 32.1 | |
| 2002 | 59.6 | 57.9 | 44.1 | 66.5 | 60.4 | 5.4 | 4.3 | 10.4 | 6.4 | 5.9 | 35.0 | 37.8 | 45.5 | 27.1 | 33.7 | |
| 1999-2002 | 60.7 | 65.0 | 44.7 | 65.4 | 61.9 | 6.4 | 5.0 | 9.2 | 7.7 | 6.8 | 32.9 | 30.1 | 46.0 | 26.9 | 31.3 | |
| Gentamicin | 1999 | 71.9 | 73.0 | 69.7 | 70.9 | 71.8 | 9.9 | 10.3 | 18.4 | 10.3 | 10.2 | 18.2 | 16.7 | 11.8 | 18.8 | 18.0 |
| 2000 | 69.3 | 63.3 | 83.1 | 67.5 | 67.8 | 9.0 | 9.3 | 4.6 | 10.5 | 9.6 | 21.7 | 27.4 | 12.3 | 21.9 | 22.6 | |
| 2001 | 74.9 | 75.3 | 68.4 | 67.1 | 72.0 | 8.3 | 6.1 | 13.2 | 10.0 | 9.0 | 16.8 | 18.6 | 18.4 | 23.0 | 19.0 | |
| 2002 | 72.9 | 69.4 | 65.2 | 76.0 | 72.9 | 10.8 | 8.4 | 16.4 | 9.2 | 10.4 | 16.3 | 22.1 | 18.4 | 14.8 | 16.7 | |
| 1999-2002 | 72.8 | 70.1 | 67.2 | 70.7 | 71.5 | 9.6 | 8.3 | 14.7 | 9.9 | 9.8 | 17.6 | 21.6 | 18.1 | 19.5 | 18.7 | |
| Imipenem | 1999 | 76.7 | 80.4 | 85.5 | 83.6 | 79.4 | 6.0 | 3.9 | 3.9 | 6.8 | 5.9 | 17.3 | 15.7 | 10.5 | 9.5 | 14.7 |
| 2000 | 77.8 | 73.5 | 87.7 | 86.4 | 80.6 | 4.5 | 5.6 | 1.5 | 4.0 | 4.4 | 17.7 | 20.8 | 10.8 | 9.6 | 15.0 | |
| 2001 | 79.0 | 75.8 | 70.1 | 84.5 | 79.7 | 7.4 | 5.1 | 18.4 | 4.7 | 7.1 | 13.7 | 19.2 | 11.5 | 10.8 | 13.1 | |
| 2002 | 76.7 | 68.2 | 71.0 | 86.6 | 78.2 | 7.7 | 5.0 | 18.2 | 5.1 | 7.4 | 15.6 | 26.8 | 10.8 | 8.3 | 14.4 | |
| 1999-2002 | 77.6 | 73.3 | 71.4 | 85.5 | 79.3 | 6.8 | 5.0 | 17.5 | 4.9 | 6.5 | 15.6 | 21.7 | 11.1 | 9.5 | 14.2 | |
| Piperacillin | 1999 | 81.1 | 85.6 | 94.7 | 90.1 | 84.6 | -b | - | - | - | - | 18.9 | 14.4 | 5.3 | 9.9 | 15.4 |
| 2000 | 80.8 | 77.0 | 84.6 | 88.4 | 83.2 | - | - | - | - | - | 19.2 | 23.0 | 15.4 | 11.6 | 16.8 | |
| 2001 | 83.5 | 77.2 | 82.2 | 87.1 | 83.9 | - | - | - | - | - | 16.5 | 22.8 | 17.8 | 12.9 | 16.1 | |
| 2002 | 83.5 | 73.5 | 82.9 | 91.1 | 84.5 | - | - | - | - | - | 16.5 | 26.5 | 17.1 | 8.9 | 15.5 | |
| 1999-2002 | 82.7 | 77.1 | 83.0 | 89.1 | 84.1 | - | - | - | - | - | 17.3 | 22.9 | 17.0 | 10.9 | 15.9 | |
| Piperacillin-tazobactam | 1999 | 83.2 | 88.8 | 98.7 | 92.7 | 87.0 | - | - | - | - | - | 16.8 | 11.2 | 1.3 | 7.3 | 13.0 |
| 2000 | 85.3 | 84.5 | 92.3 | 91.2 | 87.5 | - | - | - | - | - | 14.7 | 15.5 | 7.7 | 8.8 | 12.5 | |
| 2001 | 89.3 | 85.9 | 88.9 | 90.9 | 89.4 | - | - | - | - | - | 10.7 | 14.1 | 11.1 | 9.1 | 10.6 | |
| 2002 | 89.3 | 85.1 | 89.6 | 94.3 | 90.3 | - | - | - | - | - | 10.7 | 14.9 | 10.4 | 5.7 | 9.7 | |
| 1999-2002 | 87.8 | 85.7 | 89.6 | 92.3 | 89.1 | - | - | - | - | - | 12.2 | 14.3 | 10.4 | 7.7 | 10.9 | |
| Ticarcillin-clavulanate | 1999 | 70.3 | 72.1 | 88.2 | 76.7 | 72.6 | - | - | - | - | - | 29.7 | 27.9 | 11.8 | 23.3 | 27.4 |
| 2000 | 68.9 | 65.1 | 78.5 | 79.6 | 72.5 | - | - | - | - | - | 31.1 | 34.9 | 21.5 | 20.4 | 27.5 | |
| 2001 | 65.8 | 65.6 | 44.5 | 77.7 | 68.0 | - | - | - | - | - | 34.2 | 34.4 | 55.5 | 22.3 | 32.0 | |
| 2002 | 65.8 | 56.9 | 50.7 | 80.1 | 67.9 | - | - | - | - | - | 34.2 | 43.1 | 49.3 | 19.9 | 32.1 | |
| 1999-2002 | 66.9 | 63.4 | 49.7 | 78.8 | 69.4 | - | - | - | - | - | 33.1 | 36.6 | 50.3 | 21.2 | 30.6 | |
| Tobramycin | 1999 | 87.6 | 88.1 | 94.7 | 85.6 | 87.2 | 2.0 | 1.5 | 1.3 | 2.8 | 2.1 | 10.4 | 10.5 | 3.9 | 11.6 | 10.7 |
| 2000 | 84.2 | 79.2 | 90.8 | 84.9 | 83.8 | 2.4 | 1.4 | 1.5 | 3.0 | 2.5 | 13.4 | 19.5 | 7.7 | 12.1 | 13.8 | |
| 2001 | 85.8 | 84.7 | 80.4 | 81.5 | 83.9 | 2.0 | 0.7 | 5.1 | 3.3 | 2.5 | 12.2 | 14.6 | 14.4 | 15.2 | 13.5 | |
| 2002 | 86.4 | 82.4 | 83.8 | 89.0 | 86.5 | 1.5 | 1.0 | 2.4 | 1.9 | 1.7 | 12.1 | 16.6 | 13.9 | 9.1 | 11.8 | |
| 1999-2002 | 86.0 | 83.1 | 82.7 | 85.3 | 85.3 | 1.9 | 1.1 | 3.6 | 2.7 | 2.1 | 12.1 | 15.8 | 13.7 | 12.0 | 12.6 | |
The percentages of susceptible, intermediate, and resistant isolates according to NCCLS breakpoints are shown. P. aeruginosa isolates were collected from non-ICU patients, ICU patients, nursing home (NH) patients, outpatients (OP), and all patients combined. The total numbers of isolates collected from non-ICU patients, ICU patients, NH patients, OP, and all patients from 1999 to 2002 follow: in 1999, 3,388, 963, 76, 1,847, and 6,274, respectively; in 2000, 4,442, 1,391, 65, 3,728, and 9,626, respectively; in 2001, 7,923, 1,577, 1,185, 4,975, and 15,660, respectively; in 2002, 9,896, 2,163, 1,269, 5,444, and 18,772, respectively. For all isolates collected in 1999 to 2002, the total numbers of isolates collected from non-ICU patients, ICU patients, NH patients, OP, and all patients combined were 25,649, 6,094, 2,595, 15,994, and 50,332, respectively.
-, NCCLS breakpoints for the susceptible, intermediate, and resistant categories unavailable.